1-20 of 20
Keywords: Galantamine
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Journal Articles
Journal Articles
Dement Geriatr Cogn Disord (2008) 25 (2): 178–185.
Published Online: 14 January 2008
...A. Kertesz; D. Morlog; M. Light; M. Blair; W. Davidson; S. Jesso; R. Brashear Background/Aims: The treatment of frontotemporal dementia (FTD) has been mainly symptomatic. Small randomized or open-label case control studies of neurotransmitters have been inconclusive. We tried galantamine in the 2...
Journal Articles
Journal Articles
Dement Geriatr Cogn Disord (2006) 21 (2): 120–129.
Published Online: 20 January 2006
... Alzheimer’s disease Acetylcholine Circadian rhythm Sleep disorders Cholinesterase inhibitors Galantamine Donepezil Rivastigmine Slow-wave sleep Original Research Article Dement Geriatr Cogn Disord 2006;21:120 129 DOI: 10.1159/000090630 Accepted: July 18, 2005 Published online: January 2, 2006...
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Dement Geriatr Cogn Disord (2003) 17 (Suppl. 1): 32–39.
Published Online: 19 December 2003
... the treatment of DLB with acetylcholinesterase inhibitors. Encouraging results have been obtained from studies of DLB patients treated with rivastigmine, donepezil, and galantamine, but large-scale, controlled trials are needed to confirm the efficacy and safety of acetylcholinesterase inhibitors in patients...
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Dement Geriatr Cogn Disord (2000) 11 (Suppl. 1): 11–18.
Published Online: 14 September 2000
... therapeutic benefit in AD. One of the most potent of these allosteric modulators is galantamine. As well as modulating nAChR, galantamine inhib- its AChE. The extent to which the clinical benefits of galantamine are attributable specifically to its nicotinic effects is uncertain and requires further...
Journal Articles
Dement Geriatr Cogn Disord (2000) 11 (Suppl. 1): 19–27.
Published Online: 14 September 2000
...Sean Lilienfeld; Wim Parys Galantamine, a novel treatment for Alzheimer’s disease (AD), has a dual mechanism of action, combining allosteric modulation of nicotinic acetylcholine receptors with reversible, competitive inhibition of acetylcholinesterase. In the Phase III clinical trial programme...
Journal Articles
Dement Geriatr Cogn Disord (2000) 11 (Suppl. 1): 3–10.
Published Online: 14 September 2000
... of Geriatric Medicine, Huddinge University Hospital, bStockholm Gerontology Research Center, cHM Queen Sophia s College of Nursing, Stockholm, Sweden Key Words Alzheimer s disease W Dementia W Galantamine W Outcome measures W Activities of daily living W Caregiver burden W Behavioural disturbances W...
Journal Articles
Dement Geriatr Cogn Disord (2000) 11 (Suppl. 1): 28–34.
Published Online: 14 September 2000
... and the impact of the disease on the caregiver. Therefore, increasing attention is being paid to clinically meaningful outcome measures, such as the Disability Assessment for Dementia (DAD) scale, the Neuropsychiatric Inventory (NPI), caregiver time and the Pittsburgh Sleep Quality Index (PSQI). Galantamine...